{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:56:53Z","timestamp":1793087813341,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2022ZD0115002"],"award-info":[{"award-number":["2022ZD0115002"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32222030"],"award-info":[{"award-number":["32222030"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Microbiol"],"DOI":"10.1038\/s41564-025-02030-7","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T05:03:38Z","timestamp":1749531818000},"page":"2003-2017","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Viral evolution prediction identifies broadly neutralizing antibodies to existing and prospective SARS-CoV-2 variants"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8703-3507","authenticated-orcid":false,"given":"Fanchong","family":"Jian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Z.","family":"Wec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leilei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanling","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9084-9985","authenticated-orcid":false,"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Montes","family":"Berrueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Speidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LingZhi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8299-6627","authenticated-orcid":false,"given":"Thu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0648-1864","authenticated-orcid":false,"given":"Ayijiang","family":"Yisimayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiliang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9834-4340","authenticated-orcid":false,"given":"Sijie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhe","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9769-5141","authenticated-orcid":false,"given":"Youchun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9898-4324","authenticated-orcid":false,"given":"Simone","family":"Pecetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0635-278X","authenticated-orcid":false,"given":"Xiangxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7704-3197","authenticated-orcid":false,"given":"Laura M.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5918-1078","authenticated-orcid":false,"given":"Yunlong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"2030_CR1","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S0140-6736(22)01585-9","volume":"400","author":"JD Sachs","year":"2022","unstructured":"Sachs, J. D. et al. The Lancet Commission on lessons for the future from the COVID-19 pandemic. Lancet 400, 1224\u20131280 (2022).","journal-title":"Lancet"},{"key":"2030_CR2","first-page":"162","volume":"21","author":"AM Carabelli","year":"2023","unstructured":"Carabelli, A. M. et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat. Rev. Microbiol. 21, 162\u2013177 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"2030_CR3","doi-asserted-by":"publisher","first-page":"e395","DOI":"10.1016\/S1473-3099(23)00553-4","volume":"23","author":"Y Kaku","year":"2023","unstructured":"Kaku, Y. et al. Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against Omicron subvariants including EG.5. Lancet Infect. Dis. 23, e395\u2013e396 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"2030_CR4","doi-asserted-by":"publisher","first-page":"e1011868","DOI":"10.1371\/journal.ppat.1011868","volume":"19","author":"F Jian","year":"2023","unstructured":"Jian, F. et al. Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455\u2013456 synergistically enhances antibody evasion and ACE2 binding. PLoS Pathog. 19, e1011868 (2023).","journal-title":"PLoS Pathog."},{"key":"2030_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00813-7","author":"Y Kaku","year":"2024","unstructured":"Kaku, Y. et al. Virological characteristics of the SARS-CoV-2 JN.1 variant. Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/S1473-3099(23)00813-7 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"2030_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00744-2","author":"S Yang","year":"2023","unstructured":"Yang, S. et al. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/S1473-3099(23)00744-2 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"2030_CR7","doi-asserted-by":"crossref","unstructured":"Wang, Q. et al. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1. Cell Host Microbe 32, 315\u2013321.e3 (2024).","DOI":"10.1016\/j.chom.2024.01.014"},{"key":"2030_CR8","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa2102685","volume":"385","author":"M Dougan","year":"2021","unstructured":"Dougan, M. et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. N. Engl. J. Med. 385, 1382\u20131392 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2030_CR9","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","volume":"385","author":"A Gupta","year":"2021","unstructured":"Gupta, A. et al. Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N. Engl. J. Med. 385, 1941\u20131950 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2030_CR10","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa2035002","volume":"384","author":"DM Weinreich","year":"2020","unstructured":"Weinreich, D. M. et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. N. Engl. J. Med. 384, 238\u2013251 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2030_CR11","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41587-020-0512-5","volume":"38","author":"B Kelley","year":"2020","unstructured":"Kelley, B. Developing therapeutic monoclonal antibodies at pandemic pace. Nat. Biotechnol. 38, 540\u2013545 (2020).","journal-title":"Nat. Biotechnol."},{"key":"2030_CR12","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1038\/s41591-022-01792-5","volume":"28","author":"T Bruel","year":"2022","unstructured":"Bruel, T. et al. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat. Med. 28, 1297\u20131302 (2022).","journal-title":"Nat. Med."},{"key":"2030_CR13","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","volume":"602","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657\u2013663 (2022).","journal-title":"Nature"},{"key":"2030_CR14","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","volume":"608","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 608, 593\u2013602 (2022).","journal-title":"Nature"},{"key":"2030_CR15","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","volume":"604","author":"S Iketani","year":"2022","unstructured":"Iketani, S. et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 604, 553\u2013556 (2022).","journal-title":"Nature"},{"key":"2030_CR16","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41579-022-00809-7","volume":"21","author":"M Cox","year":"2023","unstructured":"Cox, M. et al. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nat. Rev. Microbiol. 21, 112\u2013124 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"2030_CR17","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41586-021-04386-2","volume":"602","author":"E Cameroni","year":"2022","unstructured":"Cameroni, E. et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 602, 664\u2013670 (2022).","journal-title":"Nature"},{"key":"2030_CR18","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1126\/science.abm8143","volume":"375","author":"YJ Park","year":"2022","unstructured":"Park, Y. J. et al. Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry. Science 375, 449\u2013454 (2022).","journal-title":"Science"},{"key":"2030_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.add5446","volume":"7","author":"S Luo","year":"2022","unstructured":"Luo, S. et al. An antibody from single human VH-rearranging mouse neutralizes all SARS-CoV-2 variants through BA.5 by inhibiting membrane fusion. Sci. Immunol. 7, eadd5446 (2022).","journal-title":"Sci. Immunol."},{"key":"2030_CR20","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1016\/j.cell.2022.05.014","volume":"185","author":"R Nutalai","year":"2022","unstructured":"Nutalai, R. et al. Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. Cell 185, 2116\u20132131.e2118 (2022).","journal-title":"Cell"},{"key":"2030_CR21","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41586-022-04581-9","volume":"604","author":"Q Hong","year":"2022","unstructured":"Hong, Q. et al. Molecular basis of receptor binding and antibody neutralization of Omicron. Nature 604, 546\u2013552 (2022).","journal-title":"Nature"},{"key":"2030_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110812","volume":"39","author":"K Westendorf","year":"2022","unstructured":"Westendorf, K. et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Rep. 39, 110812 (2022).","journal-title":"Cell Rep."},{"key":"2030_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ade0958","volume":"8","author":"F Bianchini","year":"2023","unstructured":"Bianchini, F. et al. Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein. Sci. Immunol. 8, eade0958 (2023).","journal-title":"Sci. Immunol."},{"key":"2030_CR24","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1016\/j.immuni.2023.09.003","volume":"56","author":"L Liu","year":"2023","unstructured":"Liu, L. et al. Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking. Immunity 56, 2442\u20132455.e2448 (2023).","journal-title":"Immunity"},{"key":"2030_CR25","first-page":"521","volume":"614","author":"Y Cao","year":"2023","unstructured":"Cao, Y. et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature 614, 521\u2013529 (2023).","journal-title":"Nature"},{"key":"2030_CR26","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","volume":"22","author":"G Li","year":"2023","unstructured":"Li, G., Hilgenfeld, R., Whitley, R. & De Clercq, E. Therapeutic strategies for COVID-19: progress and lessons learned. Nat. Rev. Drug Discov. 22, 449\u2013475 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2030_CR27","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41586-023-06753-7","volume":"625","author":"A Yisimayi","year":"2024","unstructured":"Yisimayi, A. et al. Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting. Nature 625, 148\u2013156 (2024).","journal-title":"Nature"},{"key":"2030_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111845","volume":"41","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents. Cell Rep. 41, 111845 (2022).","journal-title":"Cell Rep."},{"key":"2030_CR29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","volume":"182","author":"Y Cao","year":"2020","unstructured":"Cao, Y. et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\u2019 B cells. Cell 182, 73\u201384.e16 (2020).","journal-title":"Cell"},{"key":"2030_CR30","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41422-021-00514-9","volume":"31","author":"Y Cao","year":"2021","unstructured":"Cao, Y. et al. Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines. Cell Res. 31, 732\u2013741 (2021).","journal-title":"Cell Res."},{"key":"2030_CR31","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.cell.2020.08.012","volume":"182","author":"TN Starr","year":"2020","unstructured":"Starr, T. N. et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell 182, 1295\u20131310.e1220 (2020).","journal-title":"Cell"},{"key":"2030_CR32","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/s41590-023-01449-6","volume":"24","author":"B Ju","year":"2023","unstructured":"Ju, B. et al. Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against Omicron subvariants. Nat. Immunol. 24, 690\u2013699 (2023).","journal-title":"Nat. Immunol."},{"key":"2030_CR33","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41577-022-00784-3","volume":"23","author":"Y Chen","year":"2023","unstructured":"Chen, Y. et al. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nat. Rev. Immunol. 23, 189\u2013199 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"2030_CR34","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1080\/22221751.2020.1830715","volume":"9","author":"H Li","year":"2020","unstructured":"Li, H. et al. Establishment of replication-competent vesicular stomatitis virus-based recombinant viruses suitable for SARS-CoV-2 entry and neutralization assays. Emerg. Microbes Infect. 9, 2269\u20132277 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"2030_CR35","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41586-021-04005-0","volume":"600","author":"F Schmidt","year":"2021","unstructured":"Schmidt, F. et al. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. Nature 600, 512\u2013516 (2021).","journal-title":"Nature"},{"key":"2030_CR36","doi-asserted-by":"crossref","unstructured":"Jian, F. et al. Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1. Nature 637, 921\u2013929 (2024).","DOI":"10.1038\/s41586-024-08315-x"},{"key":"2030_CR37","doi-asserted-by":"crossref","unstructured":"Taylor, A. L. & Starr, T. N. Deep mutational scanning of SARS-CoV-2 Omicron BA.2.86 and epistatic emergence of the KP.3 variant. Virus Evol. 10, veae067 (2024).","DOI":"10.1093\/ve\/veae067"},{"key":"2030_CR38","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","volume":"588","author":"CO Barnes","year":"2020","unstructured":"Barnes, C. O. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588, 682\u2013687 (2020).","journal-title":"Nature"},{"key":"2030_CR39","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1126\/science.abd2321","volume":"369","author":"M Yuan","year":"2020","unstructured":"Yuan, M. et al. Structural basis of a shared antibody response to SARS-CoV-2. Science 369, 1119\u20131123 (2020).","journal-title":"Science"},{"key":"2030_CR40","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jmb.2003.10.007","volume":"334","author":"M Zemlin","year":"2003","unstructured":"Zemlin, M. et al. Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures. J. Mol. Biol. 334, 733\u2013749 (2003).","journal-title":"J. Mol. Biol."},{"key":"2030_CR41","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.cell.2022.06.005","volume":"185","author":"A Tuekprakhon","year":"2022","unstructured":"Tuekprakhon, A. et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell 185, 2422\u20132433.e2413 (2022).","journal-title":"Cell"},{"key":"2030_CR42","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.cell.2020.09.035","volume":"183","author":"S Du","year":"2020","unstructured":"Du, S. et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell 183, 1013\u20131023.e1013 (2020).","journal-title":"Cell"},{"key":"2030_CR43","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","volume":"386","author":"MJ Levin","year":"2022","unstructured":"Levin, M. J. et al. Intramuscular AZD7442 (tixagevimab\u2013cilgavimab) for prevention of COVID-19. N. Engl. J. Med. 386, 2188\u20132200 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2030_CR44","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg2783","volume":"15","author":"P Schmidt","year":"2023","unstructured":"Schmidt, P. et al. Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers. Sci. Transl. Med. 15, eadg2783 (2023).","journal-title":"Sci. Transl. Med."},{"key":"2030_CR45","unstructured":"Roopenian, D. C., Christianson, G. J. & Sproule, T. J. in Mouse Models for Drug Discovery: Methods and Protocols (eds Proetzel, G. & Wiles, M. V.) 93\u2013104 (Humana Press, 2010)."},{"key":"2030_CR46","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-021-01573-6","volume":"27","author":"A August","year":"2021","unstructured":"August, A. et al. A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against chikungunya virus. Nat. Med. 27, 2224\u20132233 (2021).","journal-title":"Nat. Med."},{"key":"2030_CR47","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aaw6647","volume":"4","author":"N Kose","year":"2019","unstructured":"Kose, N. et al. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection. Sci. Immunol. 4, eaaw6647 (2019).","journal-title":"Sci. Immunol."},{"key":"2030_CR48","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1056\/NEJMoa2109682","volume":"385","author":"MP O\u2019Brien","year":"2021","unstructured":"O\u2019Brien, M. P. et al. Subcutaneous REGEN-COV antibody combination to prevent COVID-19. N. Engl. J. Med. 385, 1184\u20131195 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2030_CR49","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad314","volume":"10","author":"MG Ison","year":"2023","unstructured":"Ison, M. G. et al. Prevention of COVID-19 following a single intramuscular administration of adintrevimab: results from a phase 2\/3 randomized, double-blind, placebo-controlled trial (EVADE). Open Forum Infect. Dis. 10, ofad314 (2023).","journal-title":"Open Forum Infect. Dis."},{"key":"2030_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101253","volume":"4","author":"CE Deal","year":"2023","unstructured":"Deal, C. E. et al. An mRNA-based platform for the delivery of pathogen-specific IgA into mucosal secretions. Cell Rep. Med. 4, 101253 (2023).","journal-title":"Cell Rep. Med."},{"key":"2030_CR51","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1080\/22221751.2020.1743767","volume":"9","author":"J Nie","year":"2020","unstructured":"Nie, J. et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg. Microbes Infect. 9, 680\u2013686 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"2030_CR52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2103154118","volume":"118","author":"E Andreano","year":"2021","unstructured":"Andreano, E. et al. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma. Proc. Natl Acad. Sci. USA 118, e2103154118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2030_CR53","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","volume":"27","author":"LJ Reed","year":"1938","unstructured":"Reed, L. J. & Muench, H. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 27, 493\u2013497 (1938).","journal-title":"Am. J. Epidemiol."},{"key":"2030_CR54","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1021\/acsmedchemlett.9b00681","volume":"11","author":"A Brai","year":"2020","unstructured":"Brai, A. et al. Exploring the implication of DDX3X in DENV infection: discovery of the first-in-class DDX3X fluorescent inhibitor. ACS Med. Chem. Lett. 11, 956\u2013962 (2020).","journal-title":"ACS Med. Chem. Lett."},{"key":"2030_CR55","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.3390\/vaccines11071133","volume":"11","author":"X Wu","year":"2023","unstructured":"Wu, X. et al. Development of a bioluminescent imaging mouse model for SARS-CoV-2 infection based on a pseudovirus system. Vaccines 11, 1133 (2023).","journal-title":"Vaccines"},{"key":"2030_CR56","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1073\/pnas.92.10.4477","volume":"92","author":"ND Lawson","year":"1995","unstructured":"Lawson, N. D., Stillman, E. A., Whitt, M. A. & Rose, J. K. Recombinant vesicular stomatitis viruses from DNA. Proc. Natl Acad. Sci. USA 92, 4477\u20134481 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2030_CR57","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.cell.2022.01.019","volume":"185","author":"Z Cui","year":"2022","unstructured":"Cui, Z. et al. Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron. Cell 185, 860\u2013871.e813 (2022).","journal-title":"Cell"},{"key":"2030_CR58","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz6893","volume":"6","author":"J Nelson","year":"2020","unstructured":"Nelson, J. et al. Impact of mRNA chemistry and manufacturing process on innate immune activation. Sci. Adv. 6, eaaz6893 (2020).","journal-title":"Sci. Adv."},{"key":"2030_CR59","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","volume":"26","author":"S Sabnis","year":"2018","unstructured":"Sabnis, S. et al. A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol. Ther. 26, 1509\u20131519 (2018).","journal-title":"Mol. Ther."},{"key":"2030_CR60","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/antib11040067","volume":"11","author":"E Narayanan","year":"2022","unstructured":"Narayanan, E. et al. Rational design and in vivo characterization of mRNA-encoded broadly neutralizing antibody combinations against HIV-1. Antibodies 11, 67 (2022).","journal-title":"Antibodies"},{"key":"2030_CR61","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.06.040","volume":"170","author":"JM Richner","year":"2017","unstructured":"Richner, J. M. et al. Vaccine mediated protection against Zika virus-induced congenital disease. Cell 170, 273\u2013283.e212 (2017).","journal-title":"Cell"},{"key":"2030_CR62","doi-asserted-by":"publisher","first-page":"1114\u20131125.e10","DOI":"10.1016\/j.cell.2017.02.017","volume":"168","author":"JM Richner","year":"2017","unstructured":"Richner, J. M. et al. Modified mRNA vaccines protect against Zika virus infection. Cell 168, 1114\u20131125.e10 (2017).","journal-title":"Cell"},{"key":"2030_CR63","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jviromet.2010.08.006","volume":"169","author":"MA Whitt","year":"2010","unstructured":"Whitt, M. A. Generation of VSV pseudotypes using recombinant \u0394G-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J. Virol. Methods 169, 365\u2013374 (2010).","journal-title":"J. Virol. Methods"},{"key":"2030_CR64","doi-asserted-by":"publisher","unstructured":"Jian, F., & Cao, Y. Resources for \"Viral evolution prediction identifies broadly neutralizing antibodies to existing and prospective SARS-CoV-2 variants\". Zenodo https:\/\/doi.org\/10.5281\/zenodo.15294998 (2025).","DOI":"10.5281\/zenodo.15294998"}],"container-title":["Nature Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41564-025-02030-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-025-02030-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-025-02030-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T17:48:55Z","timestamp":1757180935000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41564-025-02030-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":64,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["2030"],"URL":"https:\/\/doi.org\/10.1038\/s41564-025-02030-7","relation":{},"ISSN":["2058-5276"],"issn-type":[{"value":"2058-5276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]},"assertion":[{"value":"29 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.C. is listed as an inventor for provisional patent applications of SARS-CoV-2 RBD-specific antibodies involved in this study, including BD55-1205. The patent of BD55-1205 is licensed to Moderna. Y.C. is a co-founder of Singlomics Biopharmaceuticals. A.Z.W., J.H., D.M.B., D.L., T.S., L.M., T.K., S.P. and L.M.W. are full-time employees and holders of equity in Moderna Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}